Outcomes of patients with severe and critical COVID-19 treated with dexamethasone: a prospective cohort study

• Published in: Emerging microbes & infections Vol. 11; no. 1; pp. 50 - 59
• Main Authors: Martinez-Guerra, Bernardo A., Gonzalez-Lara, Maria F., Roman-Montes, Carla M., Tamez-Torres, Karla M., Dardón-Fierro, Francisco E., Rajme-Lopez, Sandra, Medrano-Borromeo, Carla, Martínez-Valenzuela, Alejandra, Ortiz-Brizuela, Edgar, Sifuentes-Osornio, Jose, Ponce-de-Leon, Alfredo
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 01.12.2022; Taylor & Francis Ltd; Taylor & Francis Group
• Subjects: Aged; Clinical Decision-Making; Cohort analysis; Comorbidity; Coronaviruses; corticosteroids; COVID-19; COVID-19 - diagnosis; COVID-19 - drug therapy; COVID-19 - epidemiology; COVID-19 - virology; Critical Illness; Dexamethasone; Dexamethasone - administration & dosage; Dexamethasone - therapeutic use; Disease Management; Female; Hospital Mortality; Hospitalization; Humans; Male; Mexico; Middle Aged; Mortality; SARS-CoV-2; SARS-CoV-2 - drug effects; Severity of Illness Index; Steroids; Treatment Outcome; COVID-19; Mexico; SARS-CoV-2; Dexamethasone; corticosteroids

Dexamethasone implementation for COVID-19 management represented a milestone but data regarding its impact and safety have not been consistently reproduced. We aimed to evaluate in-hospital mortality before and after the implementation of corticosteroid treatment (CS-T) for severe and critical COVID...